Heart Pump Device Market Size - By Type (Implanted, Extracorporeal), Device (Ventricular Assist Devices, Total Artificial Hearts, Intra-Aortic Balloon Pumps, Extracorporeal Membrane Oxygenation), Therapy, End-use & Forecast, 2024 – 2032

Heart Pump Device Market Size

Heart Pump Device Market size was valued at USD 2.2 billion in 2023 and is expected to grow at a CAGR of 17.4% between 2024 and 2032, driven by key factors such as the increase in number of heart failures and cardiovascular diseases, rise in awareness regarding heart failure treatment, and the growing R&D expenditure.
 

The prevalence of cardiovascular diseases, including heart failure, coronary artery disease, and cardiomyopathy, is steadily increasing worldwide due to factors such as aging populations, sedentary lifestyles, unhealthy dietary habits, and rising diabetic and obesity rates among others. For instance, according to the British Heart Foundation, in 2024, there are around 620 million people living with heart and circulatory diseases across the world. As the burden of cardiovascular diseases continues to rise, there is a corresponding increase in the demand for advanced treatment options, including heart pump devices, to manage heart failure and improve patient outcomes.

A heart pump device is a mechanical device designed to support or augment the function of a weakened or failing heart. These devices are used in patients with heart failure or other cardiac conditions where the heart's ability to pump blood is compromised.
 

Heart Pump Device Market Trends

Advancements in healthcare technology have played a pivotal role in shaping and improving various medical interventions, and this progress has significantly contributed to the growth and development of heart pump devices. These technological innovations have enhanced the design, durability, and overall efficacy of heart pump device, making them more efficient tools in the management of cardiovascular disorders.
 

• Technological advancements have led to the development of smaller and more portable heart pump devices. Miniaturized devices offer patients greater mobility and comfort, allowing them to lead more active lifestyles while receiving continuous cardiac support. Portable heart pump devices enable patients to manage their heart failure symptoms outside of hospital settings, improving their quality of life and reducing healthcare resource utilization.
   
• Moreover, continuous improvements in biomaterials science and engineering have resulted in heart pump devices with enhanced durability and reliability. Advanced materials such as biocompatible polymers and durable metals contribute to the longevity of heart pump components, reducing the risk of device failure and improving patient outcomes. The increased reliability of modern heart pump devices allows for long-term use and minimizes the need for device replacements, lowering overall healthcare costs. These innovative technologies represent the forefront of advancement in heart pump devices, poised to elevate their popularity and drive increased demand.
   

Heart Pump Device Market Analysis

The market by type is categorized into implanted heart pump devices and extracorporeal heart pump devices. The implanted heart pump devices segment is anticipated to reach USD 6.4 billion by 2032.
 

• Implanted heart pump devices which includes ventricular assist devices (VADs), are highly effective in providing mechanical circulatory support for patients with advanced heart failure who are ineligible for heart transplantation or awaiting donor organs. These devices augment or replace the pumping function of the heart's ventricles, improving cardiac output and circulation in patients with severe myocardial dysfunction. Implanted VADs serve as a life-saving therapy for individuals with end-stage heart failure, offering long-term support and symptom relief.
   
• Moreover, implanted heart pump devices are designed for long-term use, providing durable and reliable mechanical circulatory support for patients with chronic heart failure. Unlike temporary support devices such as extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pumps (IABPs), implanted VADs offer extended support for months to years, allowing patients to regain functional capacity and quality of life. The durability of implanted VADs reduces the need for frequent device exchanges or replacements, minimizing healthcare resource utilization and improving patient outcomes. Due to such advantages, the segment is anticipated to grow over the forecast period.
   

The heart pump device market by device is categorized into ventricular assist devices (VADs), total artificial hearts (TAHs), intra-aortic balloon pumps (IABPs), and extracorporeal membrane oxygenation (ECMO). The ventricular assist devices (VADs) segment held leading revenue share and was valued at around USD 1.5 billion in 2023.
 

• VADs are versatile devices that can provide circulatory support for either the left ventricle (LVAD), right ventricle (RVAD), or both ventricles (BiVAD), depending on the patient's specific cardiac anatomy and clinical needs. This adaptability allows healthcare providers to tailor VAD therapy to individual patient characteristics, optimizing hemodynamics and improving outcomes. The ability of VADs to support different ventricular configurations expands their applicability across diverse patient populations with varying degrees of heart failure severity.  
   
• Moreover, the clinical efficacy and safety of VAD therapy have been supported by a robust body of clinical evidence from randomized controlled trials, observational studies, and real-world registries. Clinical data demonstrate the benefits of VAD therapy in reducing mortality, improving functional capacity, and enhancing quality of life for patients with advanced heart failure. Growing clinical evidence and consensus guidelines recommend the use of VADs in appropriately selected patients, driving market adoption and utilization of these devices in heart failure management. These advantages attract patients and health professionals resulting in their increasing demand and market growth.
   

The heart pump device market by therapy is categorized into destination therapy, bridge-to-candidacy (BTC) therapy, bridge-to-transplant (BTT) therapy, bridge-to-recovery (BTR) therapy, and other therapies. The bridge-to-transplant (BTT) therapy segment held considerable share in 2023 and is set to witness robust market growth to surpass around USD 1.8 billion by 2032.
 

• BTT therapy involves the use of heart pump devices, such as ventricular assist devices (VADs), to provide temporary circulatory support for patients awaiting heart transplantation. These devices serve as a bridge to transplant, stabilizing patients with end-stage heart failure and improving their survival chances while they await donor organs. BTT therapy increases the likelihood of successful heart transplantation by maintaining patient health, optimizing organ allocation, and reducing waitlist mortality, making it an essential component of the heart transplant pathway.
   
• Moreover, BTT therapy plays a critical role in reducing waitlist mortality and improving outcomes for patients awaiting heart transplantation. Mechanical circulatory support with ventricular assist devices (VADs) stabilizes patients' clinical status, mitigates the risk of hemodynamic decompensation, and prevents sudden cardiac death while on the transplant waitlist. BTT therapy allows patients to remain medically optimized and functionally stable until a suitable donor becomes available, minimizing the risk of adverse events and increasing their chances of successful transplantation, making BBT a preferred choice for many patients and healthcare providers.
   

The heart pump device market by end-use is categorized into hospitals, cardiac centers, ambulatory surgical centers, and other end-users. The hospitals segment dominated around USD 1.2 billion in 2023.
 

• Hospitals, particularly those with specialized cardiac care facilities such as cardiovascular centers and transplant centers, are the primary settings for the diagnosis, treatment, and management of heart failure and other cardiovascular diseases. These facilities are equipped with advanced cardiac imaging technologies, cardiac catheterization labs, operating rooms, and tele-intensive care units to provide comprehensive care for patients with advanced heart failure. Hospitals play a central role in the delivery of mechanical circulatory support therapies, including heart pump devices, to patients requiring advanced cardiac interventions.
   
• Moreover, hospitals employ multidisciplinary teams of cardiovascular specialists, including cardiologists, cardiac surgeons, cardiac anesthesiologists, and advanced heart failure specialists, who collaborate to evaluate, implant, and manage heart pump devices in eligible patients. The expertise and experience of these healthcare professionals are essential for the successful implementation of mechanical circulatory support therapy, ensuring optimal patient outcomes and safety. Hospitals with specialized cardiac programs attract patients seeking advanced cardiac care and drive the demand for heart pump devices as essential treatment modalities.
   

North America heart pump device market accounted for USD 917.6 million revenue in 2023 and is predicted to witness substantial industry growth over the analysis timeline.
 

• North America is a global hub for technological innovation and medical device development, with numerous companies specializing in the design, manufacturing, and distribution of heart pump devices. The region's robust research and development ecosystem fosters continuous innovation in mechanical circulatory support technologies, leading to the development of next-generation devices with improved performance, reliability, and patient outcomes. The availability of cutting-edge heart pump devices drives market demand and adoption among healthcare providers in North America.
   
• Moreover, North America has a significant prevalence of heart failure, driven by factors such as an aging population, high rates of obesity, sedentary lifestyles, and the increasing burden of cardiovascular risk factors. The growing prevalence of heart failure underscores the need for effective treatment options, including mechanical circulatory support therapies like heart pump devices, to manage advanced stages of the disease and improve patient outcomes. The large patient population with heart failure in North America contributes to the sustained demand for heart pump devices in the region.
   

Heart Pump Device Market Share

The heart pump device industry is consolidated, with a few major multinational companies dominating the market. This consolidation reduces competition, as large corporations control the majority of market share. In such a landscape, the focus on innovation remains crucial for maintaining market leadership. These key players continuously invest in research and development to introduce advanced technologies and therapies that meet evolving clinical needs while optimizing cost-effectiveness. This emphasis on innovation allows dominant companies to solidify their market position and drive growth in the heart pump device industry.
 

Heart Pump Device Market Companies

Some of the eminent market participants operating in the heart pump device industry include:

• Abbott Laboratories
• ABIOMED
• Berlin Heart
• BiVACOR Inc.
• CARMAT
• CorWave SA
• Evaheart, Inc.
• Fresenius SE & Co. KGaA
• Getinge AB
• Jarvik Heart
• Leviticus Cardio
• LivaNova PLC
• Medtronic plc
• SynCardia Systems, LLC
• Teleflex Incorporated
   

Heart Pump Device Industry News

• In February 2024, BiVACOR announced that it has been awarded USD 13 million from the Australian Government’s Medical Research Future Fund (MRFF) to advance its total artificial heart programme. BiVACOR stated that the funding will help with the development of a wireless power source for the devices, along with supporting clinical trials. This may enable the company to develop a technological advanced product.
   
• In December 2023, CARMAT announced it will open a new production facility in Bois-d’Arcy, France. The new facility has been reviewed by the notified body DEKRA who approved it to produce the Aeson total artificial heart, a therapeutic alternative for people with end-stage biventricular heart failure. This expansion may help the company to enhanced customer base and generate revenue.
   

The heart pump device market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Implanted heart pump devices
• Extracorporeal heart pump devices

Market, By Device

• Ventricular assist devices (VADs)
  • Left ventricular assist devices (LVAD)
  • Right ventricular assist devices (RVAD)
  • Bi-ventricular assist devices (BiVAD)
  • Percutaneous ventricular assist devices (PVAD)
• Total artificial hearts (TAHs)
• Intra-aortic balloon pumps (IABPs)
• Extracorporeal membrane oxygenation (ECMO)

Market, By Therapy

• Destination therapy
• Bridge-to-candidacy (BTC) therapy
• Bridge-to-transplant (BTT) therapy
• Bridge-to-recovery (BTR) therapy
• Other therapies

Market, By End-use

• Hospitals
• Cardiac centers
• Ambulatory surgical centers
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa